PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Sepsis survivors carry elevated psychiatric risk for five years

sepsispsychiatric morbiditydepressionanxietypsychotropic medicationshypnoticssedativesantidepressantspost-intensive care syndromeICU survivorshipregister cohortSwedenmatched cohort Critical Care / ICU

Background Information

Sepsis survivors face an increased risk of developing psychiatric disorders.

Understanding the link between sepsis and subsequent psychiatric morbidity can improve post-ICU care and support strategies. Sepsis patients showed a higher risk of psychiatric events compared to controls, especially within the first year, with attenuated but elevated risk up to five years. Highlighting the need for psychiatric monitoring in sepsis survivors; however, the study relies on registry data and may not capture all potential confounders. Sepsis significantly increases the risk of psychiatric disorders, particularly within the first year post-ICU.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Wetterberg H, Nilsson A, Linder A, Lengquist M, Frigyesi A, Sundén-Cullberg J, Inghammar M

Citation: Wetterberg H, Nilsson A, Linder A, et al. Sepsis and Subsequent Psychiatric Morbidity: A Nationwide Population-Based Matched Cohort Study, 2008-2019. Critical care medicine. 2026;54(7):1527-1533. doi:10.1097/CCM.0000000000007105

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.